Clinical Trials · Mind Medicine Australia
Mind Medicine Australia logo Menu

Clinical Trials

Below you can find an overview of current trials in Australia and New Zealand:

Psilocybin trials

Study Type Trial ID or DOI Condition Year Registered Ethics Status Status Year Complete Location Sponsor n Masking Intervention Control
Phase 2 ACTRN12621001097831 Treatment-Resistant Depression 2021 Approved Not yet recruiting Ongoing VIC Swinburne University 15 Open 25mg psilocybin with psychotherapy​ None
Phase 2 ACTRN12621001358831 Generalised Anxiety Disorder 2021 Approved Not yet recruiting Ongoing VIC Monash University 72 Quadruple 25 or 30mg psilocybin with psychotherapy control with psychotherapy
Phase 2 ACTRN12619001225101 Depression and anxiety (in life-threatening illness)​ 2019 Approved Recruiting Ongoing VIC St Vincent’s Hospital Melbourne​ 40 Quadruple 25mg psilocybin with psychotherapy placebo with psychotherapy​
Phase 1 ACTRN12621000560897 Functional Neurological Disorder 2021 Approved Not yet recruiting Ongoing VIC Austin Health​ 22 Open 5, 10 then 15mg psilocybin with physiotherapy None
Phase 1 ACTRN12621000578808 Functional Neurological Disorder 2021 Approved Not yet recruiting Ongoing VIC Austin Health​ 15 Open 0.08-0.1mg/kg psilocybin with physiotherapy None
Phase 1 ACTRN12621001375842 Mechanism​ 2021 Approved Not yet recruiting Ongoing VIC Monash University​ 60 Open 19mg psilocybin with meditation 19mg psilocybin without meditation
Phase 1 No ID yet​ Mechanism 2021 Approved Recruiting Ongoing VIC Monarch Mental Health 100 - n = 100 for psilocybin arm n = 100 for MDMA arm

MDMA trials

Study Type Trial ID or DOI Condition Year Registered Ethics Status Status Year Complete Location Sponsor n Masking Intervention Control
Phase 2 ACTRN12619001334190​ Late-stage cancer patients, mood and anxiety 2019 Approved Not yet recruiting Ongoing NZ University of Otago 32 Quadruple 120mg MDMA (supplemented 60mg) with psychotherapy​ None
Phase 1/2​ ACTRN12621001078842 PTSD 2021 Approved Not yet recruiting Ongoing WA Edith Cowan University​ 4 Open 80 or 120mg MDMA (supplemented 40 or 60mg) with psychotherapy​ None
Phase 1 No ID yet​ Mechanism 2021 Approved Recruiting Ongoing VIC Monarch Mental Health 100 - n = 100 for MDMA arm n = 100 for psilocybin arm
Phase 0 ACTRN12613000685718 Tinnitus 2013 Approved Complete 2017 NZ The University of Auckland 40 Quadruple 30 or 70mg MDMA Placebo
Observational​ ACTRN12620001068954 Attitudes of psychotherapists towards MDMA-assisted psychotherapy 2020 Approved Recruiting Ongoin NSW University of Sydney 200 Triple MDMA-assisted psychotherapy questionnaire Fabricated drug-assisted psychotherapy questionnaire​

LSD trials

Study Type Trial ID or DOI Condition Year Registered Ethics Status Status Year Complete Location Sponsor n Masking Intervention Control
Phase 1 ACTRN12621000436875 Microdose, mechanism and creativity​ 2021 Approved Not yet recruiting Ongoing NZ The University of Auckland 80 Triple 10ug LSD Placebo

Ibogaine trials

Study Type Trial ID or DOI Condition Year Registered Ethics Status Status Year Complete Location Sponsor n Masking Intervention Control
Phase 2 10.1080/00952990.2017.1310218 Addiction, opioid 2012 Approved Complete 2015 NZ University of Otago 14 Opwn 200mg ibogaine (supplementary dose 400-600mg) None
Phase 1 ACTRN12613000324718 Mechanism 2013 Approved Complete 2013 NZ University of Otago 24 Open 20mg ibogaine Placebo; or DXM control
Observational (Follow Up) 10.1080/00952990.2017.1310218​ Addiction, opioid​ 2015 Approved Complete 2016 NZ University of Otago 14 Open Addiction and depression severity at 12 month follow up post-ibogaine treatment​ None

Subscribe to our newsletter

Stay in touch with Mind Medicine Australia:

×
It's time. Make your voice heard. Lodge a submission to the TGA supporting rescheduling of MDMA and Psilocybin. Closes May 27.